Publication Name	World Journal of Gastroenterology
Manuscript ID	7321
Country	Spain

Received	2013-11-13 08:43
Peer-Review Started	2013-11-14 11:07
To Make the First Decision	2013-12-26 10:47
Return for Revision	2013-12-27 13:44
Revised	2014-01-24 04:04
Second Decision	2014-04-03 10:16
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-03 12:33
Articles in Press	2014-05-23 09:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-11 18:30
Publish the Manuscript Online	2014-07-21 17:17

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Observational Study
Article Title	Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis
Manuscript Source	Invited Manuscript
All Author List	Carlos Taxonera, David Olivares, Juan L Mendoza, Manuel Díaz-Rubio and Enrique Rey
Funding Agency and Grant Number
Corresponding Author	Carlos Taxonera, MD, PhD, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, c/Profesor Martín Lagos s/n, 28040 Madrid, Spain. carlos.taxonera@salud.madrid.org
Key Words	Crohn’s disease; Ulcerative colitis; Infliximab; Dose intensification; Costs
Core Tip	Infliximab dose intensification to counteract loss of response is well established in the management of patients with Crohn’s disease (CD). In ulcerative colitis, the need for infliximab dose intensification is less well established. The study compares for the first time the need for infliximab dose intensification for ulcerative colitis and CD in the same clinical setting. The need for infliximab dose intensification was significantly higher in patients with ulcerative colitis compared to patients with Crohn’s disease. The drug administration costs were also higher in patients with ulcerative colitis. Our data provide a rational basis for economic planning in patients with ulcerative colitis selected for anti-tumor necrosis factor-? therapy.
Publish Date	2014-07-21 17:17
Citation	Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177
URL	http://www.wjgnet.com/1007-9327/full/v20/i27/9170.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i27.9170

Full Article (PDF)	WJG-20-9170.pdf
Full Article (Word)	WJG-20-9170.doc
Manuscript File	7321-Review.doc
Answering Reviewers	7321-Answering reviewers.pdf
Copyright License Agreement	7321-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20131112234643.pdf
Peer-review Report	7321-Peer reviews.pdf
Scientific Editor Work List	7321-Scientific editor work list.doc